David J Cote1,2,3, Mary K Downer4,5,6, Timothy R Smith7, Stephanie A Smith-Warner5,6, Kathleen M Egan8, Meir J Stampfer4,5,6. 1. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. david_cote@hms.harvard.edu. 2. Department of Epidemiology, Harvard T. H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, USA. david_cote@hms.harvard.edu. 3. Computational Neurosciences Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. david_cote@hms.harvard.edu. 4. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 5. Department of Epidemiology, Harvard T. H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, USA. 6. Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, USA. 7. Computational Neurosciences Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 8. Division of Population Sciences, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Abstract
PURPOSE: Recent studies have suggested height as a risk factor for glioma, but less is known regarding body mass index (BMI) or other anthropomorphic measures. We evaluated the association between body habitus and risk of glioma. METHODS: We evaluated the association of measures of height, BMI, waist circumference, and somatotypes with risk of glioma in two prospective cohorts, the Nurses' Health Study and the Health Professionals Follow-Up Study. RESULTS: We documented 508 incident cases of glioma (321 glioblastoma [GBM]). In both cohorts, we found no significant association between adult BMI or waist circumference and risk of glioma, with pooled HR for BMI of 1.08 (95% CI 0.85-1.38 comparing ≥ 30 to < 25 kg/m2) and for waist circumference of 1.05 (95% CI 0.80-1.37 highest vs. lowest quintile). Higher young adult BMI (at age 18 in NHS and 21 in HPFS) was associated with modestly increased risk of glioma in the pooled cohorts (pooled HR 1.35, 95% CI 1.06-1.72 comparing ≥ 25 kg/m2 vs. less; HR 1.34 for women and 1.37 for men). Analysis of body somatotypes suggested reduced risk of glioma among women with heavier body types at all ages this measure was assessed (HRs ranging from 0.52 to 0.65 comparing highest tertile to lowest tertile), but no significant association among men. Height was associated with increased risk of glioma among women (HR 1.09, 95% CI 1.04-1.14 per inch), but not significantly among men. Within the 8 years prior to diagnosis, cases had no material weight loss compared to non-cases. All results were similar when limited to GBM. CONCLUSION: Adult BMI and waist circumference were not associated with glioma. Higher BMI at age 21 for men and at age 18 for women was modestly associated with risk in the pooled cohort. Based on body somatotypes, however, women with heavier body types during childhood and young adulthood may be at lower risk of glioma, although this association was not observed later in life with measurements of BMI. Greater height was associated with increased risk, and the trend was more pronounced in women.
PURPOSE: Recent studies have suggested height as a risk factor for glioma, but less is known regarding body mass index (BMI) or other anthropomorphic measures. We evaluated the association between body habitus and risk of glioma. METHODS: We evaluated the association of measures of height, BMI, waist circumference, and somatotypes with risk of glioma in two prospective cohorts, the Nurses' Health Study and the Health Professionals Follow-Up Study. RESULTS: We documented 508 incident cases of glioma (321 glioblastoma [GBM]). In both cohorts, we found no significant association between adult BMI or waist circumference and risk of glioma, with pooled HR for BMI of 1.08 (95% CI 0.85-1.38 comparing ≥ 30 to < 25 kg/m2) and for waist circumference of 1.05 (95% CI 0.80-1.37 highest vs. lowest quintile). Higher young adult BMI (at age 18 in NHS and 21 in HPFS) was associated with modestly increased risk of glioma in the pooled cohorts (pooled HR 1.35, 95% CI 1.06-1.72 comparing ≥ 25 kg/m2 vs. less; HR 1.34 for women and 1.37 for men). Analysis of body somatotypes suggested reduced risk of glioma among women with heavier body types at all ages this measure was assessed (HRs ranging from 0.52 to 0.65 comparing highest tertile to lowest tertile), but no significant association among men. Height was associated with increased risk of glioma among women (HR 1.09, 95% CI 1.04-1.14 per inch), but not significantly among men. Within the 8 years prior to diagnosis, cases had no material weight loss compared to non-cases. All results were similar when limited to GBM. CONCLUSION: Adult BMI and waist circumference were not associated with glioma. Higher BMI at age 21 for men and at age 18 for women was modestly associated with risk in the pooled cohort. Based on body somatotypes, however, women with heavier body types during childhood and young adulthood may be at lower risk of glioma, although this association was not observed later in life with measurements of BMI. Greater height was associated with increased risk, and the trend was more pronounced in women.
Entities:
Keywords:
Body habitus; Body mass index; Glioblastoma; Glioma; Height; Waist circumference; Weight
Authors: Quinn T Ostrom; Haley Gittleman; Jordan Xu; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2016-10-01 Impact factor: 12.300
Authors: M J Stampfer; W C Willett; F E Speizer; D C Dysert; R Lipnick; B Rosner; C H Hennekens Journal: Am J Epidemiol Date: 1984-05 Impact factor: 4.897
Authors: Judith Schwartzbaum; Fredrik Jonsson; Anders Ahlbom; Susan Preston-Martin; Beatrice Malmer; Stefan Lönn; Karin Söderberg; Maria Feychting Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-03 Impact factor: 4.254
Authors: Brian M Wolpin; Andrew T Chan; Patricia Hartge; Stephen J Chanock; Peter Kraft; David J Hunter; Edward L Giovannucci; Charles S Fuchs Journal: J Natl Cancer Inst Date: 2009-03-10 Impact factor: 13.506
Authors: Steven C Moore; Preetha Rajaraman; Robert Dubrow; Amy S Darefsky; Corinna Koebnick; Albert Hollenbeck; Arthur Schatzkin; Michael F Leitzmann Journal: Cancer Res Date: 2009-10-06 Impact factor: 12.701
Authors: Vineet Tyagi; Jason Theobald; James Barger; Mark Bustoros; N Sumru Bayin; Aram S Modrek; Michael Kader; Erich G Anderer; Bernadine Donahue; Girish Fatterpekar; Dimitris G Placantonakis Journal: Surg Neurol Int Date: 2016-08-26
Authors: David J Cote; Quinn T Ostrom; Haley Gittleman; Kelsey R Duncan; Travis S CreveCoeur; Carol Kruchko; Timothy R Smith; Meir J Stampfer; Jill S Barnholtz-Sloan Journal: Cancer Date: 2019-06-17 Impact factor: 6.860
Authors: David J Cote; Alaina M Bever; Kathryn M Wilson; Timothy R Smith; Stephanie A Smith-Warner; Meir J Stampfer Journal: Int J Cancer Date: 2019-07-26 Impact factor: 7.396
Authors: Quinn T Ostrom; Maral Adel Fahmideh; David J Cote; Ivo S Muskens; Jeremy M Schraw; Michael E Scheurer; Melissa L Bondy Journal: Neuro Oncol Date: 2019-11-04 Impact factor: 12.300
Authors: David J Cote; Timothy R Smith; Ursula B Kaiser; Edward R Laws; Meir J Stampfer Journal: J Clin Endocrinol Metab Date: 2021-03-25 Impact factor: 5.958
Authors: Claudine M Samanic; David J Cote; Jordan H Creed; Meir J Stampfer; Molin Wang; Stephanie A Smith-Warner; Kathleen M Egan Journal: Cancer Causes Control Date: 2021-05-20 Impact factor: 2.532
Authors: Ivo S Muskens; Mi Zhou; Lucie Mccoy; Paige M Bracci; Helen M Hansen; W James Gauderman; John K Wiencke; Margaret R Wrensch; Joseph L Wiemels Journal: Neurooncol Adv Date: 2019-09-29